BIOLIFE SOLUTIONS INC (BLFS) Stock Price & Overview

NASDAQ:BLFSUS09062W2044

Current stock price

18.78 USD
+0.19 (+1.02%)
At close:
18.78 USD
0 (0%)
After Hours:

The current stock price of BLFS is 18.78 USD. Today BLFS is up by 1.02%. In the past month the price decreased by -16.61%. In the past year, price decreased by -10.06%.

BLFS Key Statistics

52-Week Range17.86 - 29.62
Current BLFS stock price positioned within its 52-week range.
1-Month Range17.86 - 21.695
Current BLFS stock price positioned within its 1-month range.
Market Cap
907.074M
P/E
89.43
Fwd P/E
125.53
EPS (TTM)
0.21
Dividend Yield
N/A

BLFS Stock Performance

Today
+1.02%
1 Week
-2.03%
1 Month
-16.61%
3 Months
-21.39%
Longer-term
6 Months -29.37%
1 Year -10.06%
2 Years +1.24%
3 Years -13.66%
5 Years -47.83%
10 Years +926.23%

BLFS Stock Chart

BIOLIFE SOLUTIONS INC / BLFS Daily stock chart

BLFS Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to BLFS. When comparing the yearly performance of all stocks, BLFS is a bad performer in the overall market: 82.28% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

BLFS Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to BLFS. While BLFS has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BLFS Earnings

On February 26, 2026 BLFS reported an EPS of 0.22 and a revenue of 24.76M. The company beat EPS expectations (1095.32% surprise) and beat revenue expectations (0.81% surprise).

Next Earnings DateMay 6, 2026
Last Earnings DateFeb 26, 2026
PeriodQ4 / 2025
EPS Reported$0.22
Revenue Reported24.764M
EPS Surprise 1,095.32%
Revenue Surprise 0.81%

BLFS Forecast & Estimates

16 analysts have analysed BLFS and the average price target is 33.05 USD. This implies a price increase of 75.97% is expected in the next year compared to the current price of 18.78.

For the next year, analysts expect an EPS growth of -28.76% and a revenue growth 18.24% for BLFS


Analysts
Analysts83.75
Price Target33.05 (75.99%)
EPS Next Y-28.76%
Revenue Next Year18.24%

BLFS Groups

Sector & Classification

BLFS Financial Highlights

Over the last trailing twelve months BLFS reported a non-GAAP Earnings per Share(EPS) of 0.21. The EPS increased by 141.18% compared to the year before.


Income Statements
Revenue(TTM)96.21M
Net Income(TTM)-4.59M
Industry RankSector Rank
PM (TTM) N/A
ROA -1.13%
ROE -1.24%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-15.38%
Sales Q2Q%9.03%
EPS 1Y (TTM)141.18%
Revenue 1Y (TTM)-0.89%

BLFS Ownership

Ownership
Inst Owners107.04%
Shares48.30M
Float46.93M
Ins Owners2.7%
Short Float %6.51%
Short Ratio7.08

About BLFS

Company Profile

BLFS logo image BioLife Solutions, Inc. engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. The company is headquartered in Bothell, Washington and currently employs 155 full-time employees. The firm facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the regenerative medicine market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal cryogenic vials, which are rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company’s ThawSTAR product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.

Company Info

IPO: 1989-11-22

BIOLIFE SOLUTIONS INC

Suite 310, 3303 Monte Villa Parkway

Bothell WASHINGTON 98021 US

CEO: Michael Rice

Employees: 155

BLFS Company Website

BLFS Investor Relations

Phone: 14254011400

BIOLIFE SOLUTIONS INC / BLFS FAQ

What does BIOLIFE SOLUTIONS INC do?

BioLife Solutions, Inc. engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. The company is headquartered in Bothell, Washington and currently employs 155 full-time employees. The firm facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the regenerative medicine market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal cryogenic vials, which are rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company’s ThawSTAR product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.


Can you provide the latest stock price for BIOLIFE SOLUTIONS INC?

The current stock price of BLFS is 18.78 USD. The price increased by 1.02% in the last trading session.


What is the dividend status of BIOLIFE SOLUTIONS INC?

BLFS does not pay a dividend.


What is the ChartMill rating of BIOLIFE SOLUTIONS INC stock?

BLFS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 5 out of 10.


What sector and industry does BIOLIFE SOLUTIONS INC belong to?

BIOLIFE SOLUTIONS INC (BLFS) operates in the Health Care sector and the Life Sciences Tools & Services industry.


Should I buy BLFS stock?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BLFS.


What is the employee count for BLFS stock?

BIOLIFE SOLUTIONS INC (BLFS) currently has 155 employees.